{
    "Question": "Should patients with MTX-naïve and non-MTX csDMARDs exposed RA and moderate to high disease activity, receive long-term (≥ 3 months) low dose (≤ 10mg per day) GCs and mono- or combination csDMARDs or mono or combination csDMARDs alone?",
    "Comparison": 
    {
        "Mono or combination csDMARDs with long-term (≥ 3 months) low dose (≤ 10mg per day) GCs versus mono or combination csDMARDs alone (i.e. without long-term GCs). ": 
            {
                "filename": "PICO 8b_Comparison 1.json",
                "Explanations": 
                {
                    "a": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Small sample size.",
                    "b": "csDMARD includes SSZ with long-term (>=3 months) prednisone (7mg/day).",
                    "c": "csDMARD monotherapy includes SSZ."
                }
            }
    },
    "References": 
    {
        "1": "Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Annals of the Rheumatic Diseases. 2004;63(7):797."
    }
}